Which 5-ASA? Understanding the choices in ulcerative colitis therapy-Reference-Cited by-同舟云学术

Which 5-ASA? Understanding the choices in ulcerative colitis therapy

Published:2014-06-02 Issue:5 Volume:12 Page:17-26
ISSN:1479-5248
Container-title:Gastrointestinal Nursing
language:en
Short-container-title:Gastrointestinal Nursing

Author:

Sidhu Prabhjot Singh¹,Karwa Ravi²,Kenneth Victoria³,Oxley Debi⁴,Agrawal Anurag⁵

Affiliation:

1. Specialist Registrar in Gastroenterology, Department of Gastroenterology and Endoscopy, Doncaster Royal Infirmary, Doncaster, England

2. Associate Specialist in Gastroenterology, Department of Gastroenterology and Endoscopy, Doncaster Royal Infirmary, Doncaster, England

3. Sister in Endoscopy, Department of Gastroenterology and Endoscopy, Doncaster Royal Infirmary, Doncaster, England

4. Senior Sister in Endosopy, Department of Gastroenterology and Endoscopy, Doncaster Royal Infirmary, Doncaster, England

5. Consultant Gastoenterologist and Clinical Lead in Endoscopy, Department of Gastroenterology and Endoscopy, Doncaster Royal Infirmary, Doncaster, England

Publisher

Mark Allen Group

Subject

Advanced and Specialized Nursing,Medical–Surgical Nursing

Link

http://www.magonlinelibrary.com/doi/pdf/10.12968/gasn.2014.12.5.17

Reference31 articles.

1. The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger

2. Clinical trial: A novel high-dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis

3. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study

4. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective

5. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis